Cost-effectiveness of Arg16Gly in ADRB2 pharmacogenomic-guided treatment for pediatric asthma

References

• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. DOI:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• Asthma. World Health Organisation; 2021. https://www.who.int/en/news-room/fact-sheets/detail/asthma. Accessed Jan 2, 2022.
   Google Scholar
• FMd B, Attanasi M. Asthma in childhood. Eur Respir Rev. 2016;25(139):41–47.
   PubMed Web of Science ®Google Scholar
• Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019;394(10196):407–418. DOI:10.1016/S0140-6736(19)31147-X
   PubMed Web of Science ®Google Scholar
• Institute of Environmental Health and Related Product Safety. Third nationwide survey of childhood asthma in urban areas of China. Chin J Pediatr. 2013;51(10):729–736.
   Google Scholar
• Giannini C, Mohn A, Chiarelli F. Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma. Int J Endocrinol. 2014;2014:265954.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Ko F-S. Prevalence and burden of asthma in China: time to act. Lancet. 2019;394(10196):364–366.
   PubMed Web of Science ®Google Scholar
• Xusheng M, Linxiu T, Yijun M, et al. Treatment efficacy evaluation of standardized management for children with asthma. J Clin Pediatr. 2015;33(8):706–709.
   Google Scholar
• Wake DT, Ilbawi N, Dunnenberger HM, et al. Pharmacogenomics: prescribing Precisely. Med Clin North Am. 2019;103(6):977–990.
   PubMed Web of Science ®Google Scholar
• Edris A, de Roos EW, McGeachie MJ, et al. Pharmacogenetics of inhaled corticosteroids and exacerbation risk in adults with asthma. Clin Exp Allergy. 2022;52(1):33–45. DOI:10.1111/cea.13829
   PubMed Web of Science ®Google Scholar
• Karimi L, Vijverberg SJ, Engelkes M, et al. ADRB2 haplotypes and asthma exacerbations in children and young adults: an individual participant data meta-analysis. Clin Exp Allergy. 2021;51(9):1157–1171. DOI:10.1111/cea.13965
   PubMed Web of Science ®Google Scholar
• Isidoro-García M, Sánchez-Martín A, García-Sánchez A, et al. Pharmacogenetics and the treatment of asthma. Pharmacogenomics. 2017;18(13):1271–1280.
   PubMed Web of Science ®Google Scholar
• Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax. 2006;61(11):940–944.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423–431. DOI:10.1038/clpt.2013.229
   PubMed Web of Science ®Google Scholar
• The Subspecialty Group of Respiratory Diseases. Guideline for the diagnosis and optimal management of asthma in children. Chin J Ped. 2016; 54(3):167–181.
   Google Scholar
• Li M, Wei Z. Comparative Study of Glucocorticoids Aerosols and Salmeterol and Fluticasone on Treatment of Asthma in Children. Medical Recapitulate. 2017;23(17):3529–3532.
   Google Scholar
• Lu J, Zhang X. The Advance of Montelukast in Clinical Application. Pharmacy Today. 2020;30(4):285–288.
   Google Scholar
• Zhou XJ, Qin Z, Lu J, et al. Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. Chin Med J (Engl). 2021;134(24):2954–2961.
   PubMed Web of Science ®Google Scholar
• Basu K, Palmer CN, Tavendale R, et al. Adrenergic β2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol. 2009;124(6):1188–1194.
   PubMed Web of Science ®Google Scholar
• Turner S, Francis B, Vijverberg S, et al. Childhood asthma exacerbations and the Arg-16 beta2-receptor polymorphism: a meta-analysis stratified by treatment. J Allergy Clin Immunol. 2016;138(1):107–113. DOI:10.1016/j.jaci.2015.10.045
   PubMed Web of Science ®Google Scholar
• Zuurhout MJL, Vijverberg SJH, Raaijmakers JAM, et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort. Pharmacogenomics. 2013;14(16):1965–1971. DOI:10.2217/pgs.13.200
   PubMed Web of Science ®Google Scholar
• Danyang R, Caixia T, Huiying L, et al. Effects of ADRB2 (rs1042713) Gene Polymorphism on Therapeutic Efficacy of Anticholinergic Drugs in the Treatment of Refractory Asthma Pediatric Patients. China Pharm. 2019;30(23):3265–3270.
   Google Scholar
• Lipworth BJ, Basu K, Donald HP, et al. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin sci. 2013;124(8):521–528. DOI:10.1042/CS20120528
   PubMed Web of Science ®Google Scholar
• Prina AM, Wu YT, Kralj C, et al. Dependence-and Disability-Free Life Expectancy Across Eight Low- and Middle-Income Countries: a 10/66 Study. J Aging Health. 2020;32(5–6):401–409. DOI:10.1177/0898264319825767
   PubMed Web of Science ®Google Scholar
• Arenas-Guzman R, Tosti A, Hay R, et al. Pharmacoeconomics-an aid to better decision-making. J Eur Acad Dermatol Venereol. 2005;19 Suppl 1:34–39.
   PubMed Web of Science ®Google Scholar
• Wu JH, Wu J, and Z YL. Pharmacoeconomics. Beijing: Higher Education Press; 2017.
   Google Scholar
• Wei X, Sun H, Zhuang J, et al. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clin Drug Investig. 2020;40(1):25–32. DOI:10.1007/s40261-019-00842-0
   PubMed Web of Science ®Google Scholar
• Wei X, Cai J, Sun H, et al. Cost–effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics. 2019;20(4):241–249. DOI:10.2217/pgs-2018-0138
   PubMed Web of Science ®Google Scholar
• Limdi NA, Cavallari LH, Lee CR, et al. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020;20(5):724–735. DOI:10.1038/s41397-020-0162-5
   PubMed Web of Science ®Google Scholar
• Fabbri C, Kasper S, Zohar J, et al. Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. J Affect Disord. 2021;279:722–729.
   PubMed Web of Science ®Google Scholar
• Wu AC, Gay C, Rett MD, et al. Pharmacogenomic test that predicts response to β2-agonists in adults with asthma is cost effective. Per Med. 2015;12(6):575–584.
   Web of Science ®Google Scholar
• Wu AC, Gay C, Rett MD, et al. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving. Pharmacogenomics. 2015;16(6):591–600.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022;25(1):3–9. DOI:10.1016/j.jval.2021.11.1351
   PubMed Web of Science ®Google Scholar
• Jiangtao L, Bin X, Huaping T, et al. A multi-center retrospective study of clinical characteristics and hospitalization costs of patients hospitalized for asthma exacerbation in China during 2013–2014. Chin J Tuberc Respir Dis. 2017;40(11):830–834.
   Google Scholar
• China Program for Child Development (2011-2020). Statistical monitoring report in 2019. National Bureau of statistic; 2020. http://www.stats.gov.cn/tjsj/zxfb/202012/t20201218_1810128.html. Accessed Jan 2, 2022.
   Google Scholar
• Juan D, Yanfeng Y. Cost-effectiveness analysis in child asthma treated with GINA inhaled therapeutic regimen and other therapy. Modern J Integrated Trad Chin Western Med. 2006;15(13):1738–1740.
   Google Scholar
• Zhou H, Lu Y, Wu B, et al. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. J Asthma. 2020;57(1):87–94.
   PubMed Web of Science ®Google Scholar
• Wang X, Fang H, Shen K, et al. Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China. J Med Econ. 2020;23(12):1630–1639. DOI:10.1080/13696998.2020.1830410
   PubMed Web of Science ®Google Scholar
• National Parents of Asthmatic Children KAP Project Team. Asthma control status in children and related factors in 29 cities of China. Chin J Pediatr. 2013;51(2):90–95.
   Google Scholar
• Rodríguez-Martínez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50(4):410–418.
   PubMed Web of Science ®Google Scholar
• Palmer LJ, Silverman ES, Weiss ST, et al. Pharmacogenetics of Asthma. Am J Resp Crit Care. 2002;165:861–866.
   PubMed Web of Science ®Google Scholar
• Casas M, den Dekker HT, Kruithof CJ, et al. The effect of early growth patterns and lung function on the development of childhood asthma: a population based study. Thorax. 2018;73(12):1137–1145. DOI:10.1136/thoraxjnl-2017-211216
   PubMed Web of Science ®Google Scholar
• DongSheng L, XueShan B. The General Mechanism of Reducing the Price of Medicines by Quantity Purchase and the Analysis of “4+7 Recruitment Mode”. Health Economics Research. 2019;36(8):10–12.
   Google Scholar